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Accumulation of amyloid-β (Aβ) within extracellular spaces of the brain is a hallmark of Alzheimer dis-
ease (AD). In sporadic, late-onset AD, there is little evidence for increased Aβ production, suggesting that 
decreased elimination from the brain may contribute to elevated levels of Aβ and plaque formation. Efflux 
transport of Aβ across the blood-brain barrier (BBB) contributes to Aβ removal from the brain. P-glyco-
protein (Pgp) is highly expressed on the luminal surface of brain capillary endothelial cells and contributes 
to the BBB. In Pgp-null mice, we show that [125I]Aβ40 and [125I]Aβ42 microinjected into the CNS clear at half 
the rate that they do in WT mice. When amyloid precursor protein–transgenic (APP-transgenic) mice were 
administered a Pgp inhibitor, Aβ levels within the brain interstitial fluid significantly increased within hours 
of treatment. Furthermore, APP-transgenic, Pgp-null mice had increased levels of brain Aβ and enhanced Aβ 
deposition compared with APP-transgenic, Pgp WT mice. These data establish a direct link between Pgp and 
Aβ metabolism in vivo and suggest that Pgp activity at the BBB could affect risk for developing AD as well as 
provide a novel diagnostic and therapeutic target.
*OUSPEVDUJPO
Conversion of amyloid-β (Aβ) within the extracellular spaces of 
the brain into toxic soluble and insoluble forms is accelerated at 
higher concentrations, implying that pathways influencing Aβ 
production or elimination could potentially modulate disease 
progression. Aβ is secreted from neurons into brain interstitial 
fluid (ISF), where it is eliminated by proteolytic degradation (1, 2), 
passive bulk flow (3), and active transport across the blood-brain 
barrier (BBB) (4, 5). The latter, representing efflux across the BBB 
into the periphery, appears to be a substantial pathway for elimi-
nation of CNS-derived Aβ (5). It has been demonstrated that low-
density lipoprotein receptor–related protein (LRP1) is a major Aβ 
efflux transporter at the BBB (6); however, other Aβ transporters 
likely exist as well (7, 8). P-glycoprotein (Pgp; ABCB1), the 170-kD 
protein product of the multidrug resistance-1 (MDR1) gene, when 
overexpressed in tumor cells, confers multidrug resistance due to 
efflux transport of a variety of cytotoxic agents (9). Pgp is also high-
ly expressed on the luminal surface of brain capillary endothelial 
cells, wherein Pgp functionally constitutes a major component of 
the BBB by limiting CNS penetration of various chemotherapeutic 
agents, small peptides, antibiotics, HIV protease inhibitors, and 
antidepressant drugs (10, 11). In mice, Pgp is encoded by both 
mdr1a and mdr1b, which have 90% sequence homology to each 
other and 80% to human MDR1 (10). Thus, double-knockout mice 
lacking both mdr1a and mdr1b completely eliminate Pgp activity at 
the BBB. Using an inside-out membrane vesicle preparation, Lam 
and colleagues provide in vitro biochemical data suggesting that 
Aβ may be a substrate for Pgp transport (12). Interestingly, region-
specific levels of Aβ deposition in post-mortem Alzheimer disease 
(AD) brain are inversely correlated to the level of Pgp in brain vas-
culature as assessed by immunohistochemistry (13). Herein, we 
demonstrate using Pgp-null mice that Aβ removal from the brain 
is at least partially mediated by Pgp on the BBB. Similarly, acute 
inhibition of Pgp activity, using a selective Pgp inhibitor, increases 
Aβ levels in brain ISF within hours of treatment. Furthermore, the 
lack of Pgp expression exacerbates Aβ deposition in a mouse model 
of AD. These data strongly suggest that Pgp normally transports 
Aβ out of the brain and that perturbation of Aβ efflux directly 
affects Aβ accumulation within the brain.
3FTVMUT
To directly assess the role of Pgp in transport of Aβ across the BBB, 
we first microinjected [125I]Aβ40 or [125I]Aβ42 into the brains of 
mdr1a/b–/– double-knockout (Pgp-null) mice and WT controls (7). 
[14C]inulin, a reference molecule that is neither actively transported 
across the BBB or retained within the brain, was coadministered to 
measure bulk flow of ISF in the same mice. Thirty minutes following 
coadministration of tracers, mice were sacrificed, and the content 
of each compound remaining in the brain was assessed (Figure 1, 
A and C). Significantly more [125I]Aβ40 and [125I]Aβ42 were retained 
within the brains of Pgp-null animals compared with Pgp WT mice 
Nonstandard abbreviations used: Aβ, amyloid-β; AD, Alzheimer disease; APP, 
amyloid precursor protein; BBB, blood-brain barrier; ISF, interstitial fluid; LRP1, low-
density lipoprotein receptor–related protein 1; MDR1, multidrug resistance-1; Pgp, 
P-glycoprotein; RAGE, receptor for advanced glycation endproducts.
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(P = 0.0123 and P = 0.0047, respectively), strongly suggesting that Aβ 
elimination was hindered in these animals. Removal of [3H]leucine, 
a Pgp-independent, actively transported molecule, was unaf-
fected at 10 minutes after injection (61.4% ± 3.8% and 62.7% ± 5% 
retained in Pgp WT [FVB] versus Pgp-null, respectively). Similarly, 
bulk flow pathways, accounting for less than 20% of clearance, 
appeared unchanged in the knockout animals as demonstrated by 
nearly identical levels of inulin remaining in both groups. As shown 
in Figure 1B, after passive elimination was taken into account, 31% 
of injected Aβ40 was transported across the BBB in WT mice, where-
as only approximately 14% was cleared in the Pgp-null animals 
(P = 0.0033). Similarly, 16% of Aβ42 was transported in Pgp WT mice 
compared with 6% in Pgp-null mice (Figure 1D). Compared with 
Aβ40, significantly less Aβ42 was removed from the brain in WT and 
Pgp-null mice, which is consistent with previous studies showing 
that Aβ40 is generally actively transported across the BBB more than 
Aβ42 (7). LRP1 has been previously shown to transport Aβ across 
the BBB (5, 7). While overall levels of LRP1 in brain homogenates 
were comparable (data not shown), interestingly, levels of LRP1 
decreased by 50% in brain capillaries of 2- to 3-month-old Pgp-null 
mice as compared with Pgp WT mice (Figure 1E). This decrease 
in LRP1 expression at the BBB may have partially contributed to 
decreased Aβ clearance in Pgp-null mice.
Next, we assessed how acute inhibition of Pgp activity affected 
brain ISF Aβ levels. We utilized APPsw (also called Tg2576) mice, 
which overexpress human amyloid precursor protein (APP), with 
a mutation that in humans causes an autosomal dominant form 
of early-onset familial AD (14). A selective Pgp inhibitor, XR9576 
(15), was used to block Pgp activity at the BBB in APPsw mice. 
Because brain capillary endothelial cells transport molecules out 
of the brain ISF into the periphery, we directly assessed this fluid 
for changes in Aβ levels following intravenous administration 
of XR9576 at 80 mg/kg, a dose that inhibits Pgp function at the 
BBB, as determined by [99mTc]Sestamibi analysis (data not shown). 
Using in vivo microdialysis in awake, freely moving mice (16, 17), 
we first determined a basal concentration of ISF Aβ over 5 hours, 
then treated mice with either vehicle or XR9576 and continued to 
assess ISF Aβ levels for an additional 10 hours (Figure 2A). Eight 
hours after treatment, ISF Aβ levels increased almost 30% com-
pared with vehicle-treated mice (P < 0.05), suggesting that acute 
inhibition of Pgp at the BBB caused decreased elimination of Aβ 
from brain ISF. Ten hours after treatment with either vehicle or 
XR9576, cerebral microvessels were also isolated and assessed for 
levels of LRP1 by Western blotting. LRP1 levels in endothelial cells 
did not change (Figure 2B), indicating that, in this case, the change 
in ISF Aβ levels is not attributable to LRP1 downregulation but is 
likely due to specific inhibition of Pgp.
Next, we determined whether the absence of Pgp at the BBB 
would promote Aβ deposition. We bred APPsw+/– mice to mdr1a/b–/– 
animals to produce littermate mice that were positive for the 
APPsw transgene and either Pgp-null (APPsw+/–, mdr1a/b–/–) or Pgp 
WT (APPsw+/–, mdr1a/b+/+). To confirm that transgenic expression 
of mutated human APP did not impact basal function of Pgp in 
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pharmaceutical that has been validated as a sensitive probe of Pgp 
transport function (18), were performed in 2- to 4-month-old WT 
(mdr1a/b+/+) and Pgp-null (mdr1a/b–/–) mice, both in the absence 
and presence of the APPsw+/– transgene. Normally, [99mTc]Sestamibi 
is readily transported out of the brain by Pgp. However, in Pgp-null 
animals, [99mTc]Sestamibi levels increase in the brain as it perme-
ates cerebral capillaries and is not removed effectively. Five minutes 
after intravenous bolus injection of [99mTc]Sestamibi (2 μCi), brain 
content of the tracer was 0.22% ± 0.02% injected dose/g (ID/g) in 
WT controls versus 0.85% ± 0.14% ID/g in Pgp-null mice (Figure 3). 
There was no difference in blood content of the tracer between the 
2 strains (P > 0.2). This approximately 3.5-fold increase in brain 
penetration of [99mTc]Sestamibi in Pgp-null mice was consistent 
with previous studies (19). In animals of similar age that expressed 
the APPsw+/– transgene, brain penetration of the tracer was also 
increased by approximately 3.5-fold in Pgp-null animals compared 
with those expressing Pgp (Figure 3). Thus, basal activity of Pgp 
was independent of the APPsw+/– transgene (P > 0.3).
When allowed to survive to 12 months, APPsw+/– mice exhibited 
substantial Aβ deposition throughout the neocortex and hippo-
campus (Figure 4, A and B). The area covered by Aβ immunore-
activity in the hippocampus was significantly greater in APPsw, 
Pgp-null animals compared with APPsw, Pgp WT littermates 
(P = 0.0041; Figure 4C). The amount of fibrillar Aβ, as determined 
by thioflavine S staining, was also significantly elevated in Pgp-
null animals (P = 0.0276; Figure 4D). However, when the amount 
of thioflavine S was normalized to total plaque load, there was 
not a significant difference in the percentage of fibrillar plaques 
between groups (Figure 4E). This suggests that while Pgp dele-
tion leads to greater Aβ deposition, Pgp does not preferentially 
alter the conversion of plaques into fibrillar structures. There 
was no apparent change in the amount of vascular Aβ accumula-
tion in 12-month-old Pgp-null animals; however, it remains pos-
sible that at later ages, when there is a greater amount of cerebral 
amyloid angiopathy, there may be a noticeable affect. The mass 
of insoluble Aβ42, as assessed by guanidine extraction and Aβ 
ELISA, was 2-fold greater in the hippocampus of Pgp-null ani-
mals (P = 0.0499; Figure 4F), while there was only a trend toward 
an increase in insoluble Aβ40 (P = 0.2472; Figure 4G). Carbon-
ate-extractable Aβ40 and Aβ42 was not different between these 
groups (data not shown). Similar to the hippocampus, there 
was a trend toward elevated Aβ plaque load in the neocortex of 
Pgp-null mice; however, this increase was not statistically signifi-
cant (Figure 4H). These findings indicate that abrogation of the 
Pgp transporter at the BBB gave rise to greater Aβ accumulation 
within the brain and suggest that modulation of Pgp activity can 
directly influence progression of Aβ pathology. Because genetic 
deletion of Pgp also causes a decrease in the level of LRP1 at the 
BBB (Figure 1), it remains possible that the changes in Aβ depo-
sition are due to a combined decrease in both Aβ transporters. 
In fact, these Aβ transporters may be playing a synergistic role, 
with LRP1 functional on the basolateral surface and Pgp on the 
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Pgp shares sequence homology and substantial pharmacologi-
cal cross-reactivity with several members of the ATP-binding cas-
sette superfamily of transporters that are also expressed at the 
BBB, including multidrug-resistance–associated protein-1 (MRP1, 
also known as ABCC1) (9). In 12-month-old APPsw, Pgp-null 
(APPsw+/–, mdr1a/b–/–) mice, expression of MRP1 in hippocampal 
homogenates was elevated compared with Pgp WT (APPsw+/–, 
mdr1a/b+/+) mice (P = 0.0401; data not shown). Although Pgp and 
MRP1 have overlapping pharmacological profiles, it is unknown 
whether MRP1 can also transport Aβ in vivo. In vitro studies sug-
gest that MRP1 cannot transport Aβ (12). Receptor for advanced 
glycation endproducts (RAGE), a transporter on the BBB that is 
responsible for transporting Aβ from the blood into the brain (20, 
21), was expressed at similar levels in hippocampal homogenates 
of 12-month-old APPsw, Pgp-null and APPsw, Pgp WT mice (data 
not shown). The potential contribution of each of these transport-
ers to Aβ clearance from the brain and how they might interact or 
compensate for each other requires further investigation.
%JTDVTTJPO
Herein, we demonstrate that Pgp is involved in the transport of 
Aβ across the BBB in vivo and that ablation of Pgp at the BBB 
enhances Aβ deposition. While Pgp deletion has not been reported 
in humans, several mechanisms for modulation of Pgp activity at 
the BBB could influence AD. Several Pgp single nucleotide poly-
morphisms, such as the exon 26 3435T allele, have been described 
that decrease Pgp expression and result in functional differences 
in oral absorption and disposition of drugs (22). It is conceivable 
that similar polymorphisms in Pgp could decrease Aβ transport 
out of the brain, thereby increasing the probability of plaque for-
mation. Conversely, polymorphisms that increase Pgp transport 
activity may decrease the risk of Aβ deposition and development of 
AD. A detailed genetic analysis of Pgp polymorphisms in relation 
to AD in humans could test this hypothesis.
In addition to the impact of genetic polymorphisms on Pgp activ-
ity, many commonly used drugs and herbal medicinals alter Pgp 
function. For example, dexamethasone, morphine, rifampin, quer-
cetin, and St. John’s wort are reported to enhance Pgp activity, while 
verapamil, cyclosporine A, erythromycin, fluoxetine, progesterone, 
HIV protease inhibitors, and several statins inhibit Pgp activity (for 
review, see refs. 9, 23). While some of these compounds only affect 
Pgp activity slightly in short-term assays, with chronic use or in 
combination, it is possible that these drugs could have a greater 
effect on Pgp function and, consequently, on brain Aβ levels. Since 
Pgp function can be modulated pharmacologically, there is poten-
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the brain. For example, a randomized clinical trial demonstrated 
that the antibiotic rifampin lessened cognitive decline in patients 
with mild to moderate AD after 12 months of treatment (24). This 
improvement in cognitive function did not appear to be linked to 
the drug’s antibiotic activity. Because rifampin is also a Pgp sub-
strate and inducer, the effects of rifampin on cognitive ability may 
be linked to enhanced clearance of Aβ from the brain via Pgp-medi-
ated transport. An additional advantage of modulating Pgp activity 
is that because Pgp is expressed on the luminal surface of brain 
capillary endothelial cells and not within the CNS per se, drugs may 
not be required to cross the BBB, a typical hurdle in developing 
CNS-targeted therapies. Given that a variety of genetic, therapeu-
tic, and dietary factors can influence Pgp function, thus potentially 
affecting Aβ transport, it will be interesting to determine whether 
these features correlate with the incidence of AD.
.FUIPET
Animals. All experimental procedures involving animals were approved by 
the Animal Studies Committee at Washington University and performed in 
accordance with their guidelines. We utilized 8- to 10-week-old mdr1a/b–/– 
double-knockout mice on an FVB background (Taconic) and WT controls 
(also on an FVB background) for our BBB transport studies. We also bred 
mdr1a/b–/– mice to APPsw+/– hemizygous mice (Tg2576 on a C57BL/6-SJL 
background; a generous gift from K. Ashe, University of Minnesota, Min-
neapolis, Minnesota, USA). We then bred F1 offspring from this colony to 
each other to produce littermate mdr1a/b homozygous (+/+) and double-
knockout (–/–) mice that were hemizygous for the APPsw+/– transgene. Ani-
mals were screened for the presence of APPsw as well as mdr1a and mdr1b 
genes by PCR analysis of tail DNA. Aβ content in the brain was analyzed 
when animals were 12 months old.
BBB transport. Transport of human [125I]Aβ40 [125I]Aβ42 across the BBB and 
calculations were performed as previously described (4, 8). Briefly, a guide 
cannula was implanted stereotaxically into the right caudate-putamen of 
anesthetized mice at coordinates 0.9 mm anterior to bregma, 1.9 mm lat-
eral, and 2.9 mm below the dura. Animals were allowed to recover after 
surgery prior to radiotracer studies. The clearance experiments were per-
formed before substantial chronic processes occurred, typically 4–6 hours 
following cannula implantation, to allow the BBB to at least partially repair 
and exclude large molecules (8, 16). Twelve nanomoles of [14C]inulin and 
either [125I]Aβ40 or [125I]Aβ42 was coinjected in a volume of 0.5 μl over 5 
minutes using an ultra micropump (World Precision Instruments Inc.). 
The specific activities of peptide were in the range of 80–120 μCi/μg. 
The percentage of radioactivity remaining in the brain after microin-
jection was determined as percentage recovery in brain = 100 × (Nb/Ni), 
where Nb is the radioactivity remaining in the brain at the end of the experi-
ment and Ni is the radioactivity microinjected into brain ISF, i.e., the disinte-
grations per minute for [14C]inulin and the counts per minute for trichloro-
acetic acid–precipitable [125I]radioactivity (intact Aβ). The percentage of Aβ 
cleared through the BBB was calculated as [(1 – Nb(Aβ)/Ni(Aβ)) – (1 – Nb(inulin)/
Ni(inulin))] × 100, using a standard time of 30 minutes. D-[4,5-3H]leucine 
(Amersham Biosciences) transport across the BBB was assessed using a 
method similar to that described above: 750 nmol of [3H]leucine, specific 
activity 1.16 Ci/mg, was injected in a volume of 0.5 μl followed by measure-
ment of radioactivity within the brain at 10 minutes.
ISF Aβ in vivo microdialysis. In vivo microdialysis to assess brain ISF Aβ1–x in 
the hippocampus of awake, freely moving 3-month-old APPsw+/– mice was 
performed exactly as described previously (16, 17). Aβ1–x represents all Aβ 
peptides beginning at amino acid 1 of the N-terminus with the C-terminus 
being variable, but predominantly either ending at position 40 or 42. An ini-
tial 4- to 6-hour recovery period elapsed after guide implantation and probe 
insertion to allow for tissue recovery, followed by collection of microdialysis 
samples for 5 hours at 1-hour intervals at a flow rate of 1.5 μl/min to estab-
lish basal level of ISF Aβ. XR9576 (80 mg/kg body weight; Xenova QLT Inc.; 
diluted in 5% dextrose) or vehicle was injected into the jugular vein, and an 
additional 10 one-hour microdialysis samples were collected. Concentra-
tions of ISF Aβ1–x for each mouse were expressed as the percentage of basal 
level for each mouse (mean of 5 hours prior to treatment).
[99mTc]Sestamibi transport and biodistribution. The radiopharmaceutical 
[99mTc]Sestamibi (Bristol-Myers Squibb Co.) was prepared from a 1-step 
commercial kit formulation by addition of [99mTc]TcO4– according to the 
manufacturer’s recommendations (25). Sep-Pak purification (>95%) and 
quality control of the tracer were performed as previously described (25). 
Following intravenous injection, distribution of [99mTc]Sestamibi in the 
brain and blood of Pgp WT and Pgp-null mice with or without coexpression 
of APPsw+/– was determined 5 minutes after injection as previously described 
(26, 27). Data are expressed as percent injected dose per gram tissue [(μCi 
[99mTc]Sestamibi in tissue) (μCi injected [99mTc]Sestamibi)–1 (g tissue)–1 × 100)] 
and are reported as mean ± SEM (n = 3–4) or ± range (n = 2).
Histological analysis. Tissue sections were cut in the coronal plane at 50 μm 
on a freezing sliding microtome from the genu of the corpus callosum 
through the caudal extent of the hippocampus. The percent surface area 
covered by Aβ-immunoreactivity deposits (% Aβ load), as identified with 
a mouse monoclonal antibody against the N terminus of human Aβ, 
m3D6 (Eli Lilly and Co.), was quantified following unbiased stereological 
principles as described (28). Thioflavine S staining was performed stereo-
logically and quantified as previously described (29). Aβ and thioflavine S 
load were determined in the cingulate cortex and hippocampus in 3 brain 
sections, each separated by 300 μm.
Aβ quantification. Aβ40 and Aβ42 levels in brain tissue were determined 
by sandwich ELISA as previously described (16). Briefly, m266, m2G3, or 
m21F12 were used as coating antibodies to capture Aβ1–x, Aβ40, or Aβ42, 
respectively. Biotinylated m3D6, a human-specific antibody against the 
N terminus of Aβ, was used as the reporting antibody in each ELISA. To 
evaluate the carbonate-soluble and -insoluble pools of Aβ in brain tissue, 
we performed a carbonate extraction (100 mM carbonate, 50 mM NaCl, 
protease inhibitors, pH 11.5) of hippocampal tissue (1:10, wt/vol) on ice 
followed by a 5 M guanidine, pH 8.0 extraction for 3 hours at room temp. 
Tissue samples were dounce homogenized and spun in a microcentrifuge 
at 21,000 g for 15 minutes at 4°C following each extraction.
Western blotting. Hippocampal tissue from 12-month-old APPsw, Pgp WT, 
and APPsw, Pgp-null littermates was homogenized in 150 mM NaCl, 50 mM 
Tris pH 7.4, 0.5% deoxycholic acid, 0.1% SDS, 1% Triton X-100, 2.5 mM EDTA, 
and protease inhibitors. Western blotting for MRP1, LRP1, and RAGE were 
performed using 3–8% NuPAGE Tris-Acetate gels (Invitrogen Corp.) with 30 μg 
of protein loaded per lane. Cerebral microvessels from 2- to 3-month-old Pgp 
WT (FVB) and Pgp-null mice were isolated as described (30). Microvessels 
were homogenized in cold lysis buffer: 150 mM NaCl, 50 mM Tris pH 7.4, 
0.1% SDS, 1% Triton X-100, and complete protease inhibitor cocktail (Roche 
Diagnostics Corp.). Individual protein homogenates were separated under 
nonreducing conditions, transferred to nitrocellulose membrane, and probed 
with rabbit anti–LRP1-85 (LRP, β-chain specific; EMD Biosciences Inc.), rab-
bit anti-RAGE (Santa Cruz Biotechnology Inc.), or rat anti-MRP1 (Signet Lab-
oratories), followed by goat anti-rabbit or donkey anti-rat secondary antibod-
ies conjugated to HRP (Jackson ImmunoResearch Laboratories Inc.). Mouse 
anti-tubulin (Sigma-Aldrich) or anti–β-actin (Santa Cruz Biotechnology Inc.) 
were used to detect control proteins in each lane. Bands were detected with 
Lumigen-TMA6 (Amersham Biosciences) and captured digitally using Kodak 
ImageStation 440CF. The relative absorbance of each band was detected by 
densitometry and normalized to protein loaded in each lane. Analysis was 
performed using Kodak 1D Image Analysis software version 3.6.
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Statistics. Data shown in figures represent mean ± SEM. Mann-Whitney 
U test was used to compare data between Pgp-null and WT mice, as well as 
LRP1 expression levels in endothelial cells of XR9576 and vehicle-treated 
mice. ISF Aβ levels in XR9576 and vehicle-treated mice, over the duration 
of the experiment, were compared by 2-way ANOVA followed by the Bonfer-
roni post-hoc test to compare means. P values of less than 0.05 were consid-
ered statistically significant. All statistical analyses were performed using 
Prism version 4.02 (GraphPad Software) for Windows (Microsoft Corp.).
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